American Academy of Optometry plays host to product advances
Academy 2024, the annual meeting of the American Academy of Optometry, which occurred Nov. 6 to Nov. 9, in Indianapolis, played host to many product advances.
“…Maybe it’s time to reach out to some companies to talk to them about where you can invest to be able to make a difference in your practice,” suggests Optometric Management’s Chief optometric editor April Jasper, OD, FAAO.
The highlights of these product advances:
• Alcon debuted Precision7, a one-week replacement lens available in both sphere and toric that contains the company’s 7-day Activ-Flo System. This System provides 16 hours of comfort and precise vision, even on day 7, according to Alcon. Precision7 is the latest addition to the company’s WaterInnovations portfolio of contact lenses, which “harnesses the power of water to deliver comfort, helping to outsmart Digital Device Dryness and many other challenges today’s patients face,” according to Alcon.
• Bausch + Lomb demoed its digital e-commerce marketplace, Opal, which the company released in October. Opal provides a streamlined ordering process for Bausch + Lomb contact lenses, with select Bausch + Lomb OTC products to be added in the coming months, according to the company. Specifically, it features order tracking and history, appointment reminders, automated prescription reminders, and free shipping.
• Essilor/Luxottica demoed their Nuance Audio glasses, which pair hearing solutions and prescription glasses into a frame. The audio component is completely invisible, according to the company, which says it expects the two-in-one product to be available before the year ends.
• Johnson & Johnson presented a poster showing that the blue-green appearance of the company’s Acuvue Oasys Max 1-Day contact lens facilitated patients seeing it in its blister pack. The blue-green appearance is a result of the combination of the OptiBlue Technology blue-violet light filter and a blue handling tint, according to the company.
• Visioneering Technologies Inc. revealed findings from Year 1 of its ongoing PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens (PROTECT) clinical trial. Specifically, the data reveals patient comfort, high compliance, and reduction in myopia progression regardless of pupil size. The company says it plans to release Year 2 data from the three-year PROTECT trial in early 2025. OM